中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

997 records (took 0.087 seconds)

    Compositions And Methods For Modulating Apoptosis
    181.
    发明申请
    Compositions And Methods For Modulating Apoptosis 审中-公开
    用于调节凋亡的组合物和方法

    公开(公告)号：US20140155330A1

    公开(公告)日：2014-06-05

    申请号：US14177840

    申请日：2014-02-11

    Applicant: Yeda Research and Development Co. Ltd.

    Inventor： Adi Kimchi ,  Assaf Rubinstein

    IPC: C07K14/47 ,  G01N33/566 ,  G01N33/574

    CPC classification number: C07K14/4747 ,  G01N33/566 ,  G01N33/5748

    Abstract: Peptides, compositions and methods for modulating apoptosis, useful for treating diseases or disorders characterized by dysregulated apoptosis, such as cancer or neurodegenerative diseases. Screening methods for identifying agents that mediate apoptosis by regulating Atg12 binding to Bcl-2 family members.

    Abstract translation: 用于调节凋亡的肽，组合物和方法，其可用于治疗以失调性细胞凋亡为特征的疾病或病症，例如癌症或神经变性疾病。 通过调节Atg12结合Bcl-2家族成员来鉴定介导凋亡的药剂的筛选方法。

    REVERSIBLE PEGYLATED DRUGS
    182.
    发明申请
    REVERSIBLE PEGYLATED DRUGS 有权
    可逆的PEGY药物

    公开(公告)号：US20140121352A1

    公开(公告)日：2014-05-01

    申请号：US14146396

    申请日：2014-01-02

    Applicant: YEDA RESEARCH AND DEVELOPMENT CO., LTD.

    Inventor： YORAM SHECHTER ,  MATITYAHU FRIDKIN ,  HAIM TSUBERY

    IPC: A61K47/48

    CPC classification number: A61K47/60 ,  A61K31/7036 ,  A61K38/1709 ,  A61K38/212 ,  A61K38/22 ,  A61K38/2242 ,  A61K38/2278 ,  A61K38/26 ,  A61K38/27 ,  A61K38/28 ,  A61K47/54 ,  A61K47/545 ,  C07D207/404 ,  C07D207/416 ,  C07D207/452 ,  C07D403/12

    Abstract: Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.

    Abstract translation: 可逆的聚乙二醇化药物通过衍生自选自氨基，羟基，巯基，磷酸酯和/或羧基的药物的游离官能团与对温和碱性条件敏感的基团如9-芴基甲氧基羰基（Fmoc）或2-磺基-9-芴基甲氧基羰基 （FMS），连接有PEG部分的基团。 在这些聚乙二醇化药物中，PEG部分和药物残留物不直接相互连接，而是两个残基都连接到对碱基高度敏感并在生理条件下可去除的支架Fmoc或FMS结构的不同位置。 药物优选是含有氨基的药物，最优选低分子量或中等分子量的肽和蛋白质。 提供了类似的分子，其中蛋白质载体或另一种聚合物载体取代了PEG部分。

    PHOTOSYNTHETIC ORGANISMS AND COMPOSITIONS AND METHODS OF GENERATING SAME
    183.
    发明申请
    PHOTOSYNTHETIC ORGANISMS AND COMPOSITIONS AND METHODS OF GENERATING SAME 有权
    光化学有机体及其组合物及其生成方法

    公开(公告)号：US20140088293A1

    公开(公告)日：2014-03-27

    申请号：US14093562

    申请日：2013-12-02

    Applicant: Yeda Research and Development Co. Ltd.

    Inventor： Avigdor SCHERZ ,  Oksana Shlyk-Kerner ,  IIan Samish ,  David Kaftan ,  Jorge Dinamarca

    IPC: C07K14/405

    CPC classification number: C07K14/405 ,  C07K14/195

    Abstract: An isolated polynucleotide is provided. The isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide of a Type II reaction center of a photosynthetic organism, the nucleic acid sequence being capable of imparting the type II reaction center with an activity under a temperature range different than that of the type II reaction center endogenous to the photosynthetic organism. Also provided are methods of using the sequences for generating photosynthetic organisms or tailor-made thermotolerance.

    Abstract translation: 提供了分离的多核苷酸。 分离的多核苷酸包含编码光合生物的II型反应中心的多肽的核酸序列，所述核酸序列能够使II型反应中心在不同于II型反应的温度范围内具有活性 对光合生物体内生的中心。 还提供了使用序列产生光合生物或定制耐热性的方法。

    COMBINATIONS OF ANTI ErbB ANTIBODIES FOR THE TREATMENT OF CANCER
    184.
    发明申请
    COMBINATIONS OF ANTI ErbB ANTIBODIES FOR THE TREATMENT OF CANCER 有权
    用于治疗癌症的抗ErbB抗体的组合

    公开(公告)号：US20140086917A1

    公开(公告)日：2014-03-27

    申请号：US14118243

    申请日：2012-05-16

    Applicant: Yeda Research and Development Co. Ltd.

    Inventor： Michael Sela ,  Yosef Yarden ,  Bilha Schechter ,  Ruth Maron

    IPC: A61K39/395 ,  A61N5/10

    CPC classification number: A61K39/39558 ,  A61K2039/505 ,  A61K2039/507 ,  A61N5/10 ,  C07K16/2863 ,  C07K16/32

    Abstract: An article-of-manufacture is provided. The article-of-manufacture comprises a packaging material identified for treating cancer, packaging: (i) an anti-EGFR antibody comprising the CDR sequences of anti EGFR 565 (CNCM Deposit Number I-4262); and (ii) an anti-ErbB-2 antibody comprising the CDR sequences of anti ErbB-2 L431 (CNCM Deposit Number I-4115), anti ErbB-2 L26 (CNCM Deposit Number I-4113) or anti ErbB-2 N12 (CNCM Deposit Number I-4112), or (iii) an anti-EGFR antibody comprising the CDR sequences of anti EGFR 111 (CNCM Deposit Number I-4261); and (iv) an anti-ErbB-2 antibody comprising the CDR sequences of anti ErbB-2 L431 (CNCM Deposit Number I-4115). Also provided are pharmaceutical compositions and methods of using the above antibodies as well as other antibody combinations for the treatment of cancer.

    Abstract translation: 提供制造品。 制品包括被鉴定用于治疗癌症的包装材料，包装：（i）包含抗EGFR 565（CNCM保藏号I-4262）的CDR序列的抗EGFR抗体; 和（ii）抗ErbB-2抗体，其包含抗ErbB-2 L431（CNCM保藏号I-4115），抗ErbB-2 L26（CNCM保藏号I-4113）或抗ErbB-2 N12 CNCM保藏号I-4112），或（iii）包含抗EGFR 111（CNCM存放号I-4261）的CDR序列的抗EGFR抗体; 和（iv）包含抗ErbB-2 L431（CNCM保藏号I-4115）的CDR序列的抗ErbB-2抗体。 还提供了药物组合物和使用上述抗体以及用于治疗癌症的其它抗体组合的方法。

    NUCLEIC ACID CONSTRUCT SYSTEMS CAPABLE OF DIAGNOSING OR TREATING A CELL STATE
    187.
    发明申请
    NUCLEIC ACID CONSTRUCT SYSTEMS CAPABLE OF DIAGNOSING OR TREATING A CELL STATE 审中-公开
    可诊断或治疗细胞状态的核酸构建体系

    公开(公告)号：US20130260386A1

    公开(公告)日：2013-10-03

    申请号：US13914686

    申请日：2013-06-11

    Applicant: Yeda Research and Development Co., Ltd.

    Inventor： Lior NISSIM ,  Roy Bar-Ziv

    IPC: C12Q1/68

    CPC classification number: C12Q1/6897 ,  C12N15/1055 ,  C12N15/85 ,  C12N2830/007 ,  C12N2830/008 ,  G01N33/5008 ,  G01N33/5091

    Abstract: Nucleic acid construct systems are disclosed capable of diagnosing and treating a cell state (e.g. disease state). Methods of diagnosing and treating disease states using the nucleic acid constructs described herein are also disclosed. In addition, methods of screening for agents capable of reversing a disease phenotype using the nucleic acid constructs of the present invention are disclosed.

    Abstract translation: 公开了能够诊断和治疗细胞状态（例如疾病状态）的核酸构建系统。 还公开了使用本文所述的核酸构建体诊断和治疗疾病状态的方法。 此外，公开了使用本发明的核酸构建体筛选能够逆转疾病表型的试剂的方法。

    TNF receptor-specific antibodies
    189.
    发明申请
    TNF receptor-specific antibodies 审中-公开
    TNF受体特异性抗体

    公开(公告)号：US20030228312A1

    公开(公告)日：2003-12-11

    申请号：US10423927

    申请日：2003-04-28

    Applicant: Yeda Research and Development Co. Ltd

    Inventor： David Wallach ,  Jacek Bigda ,  Igor Beletsky ,  Igor Mett ,  Hartmut Engelmann

    IPC: A61K039/395 ,  C07H021/04 ,  C12P021/02 ,  C12N005/06 ,  C07K016/24

    CPC classification number: C07K16/2866 ,  A61K38/00 ,  C07K14/7151 ,  C07K16/4258 ,  C07K2319/00

    Abstract: Antibodies to Tumor Necrosis Factor receptors (TNF-Rs) which inhibit the cytocidal effect of TNF but not its binding to the TNF-Rs, and ligands interacting with other receptors of the TNF/NGF family, are provided together with methods of producing them. The antibodies preferably bind to the fourth cysteine rich domain of the p75 TNF receptor or to the region between said fourth cysteine rich domain and the cell membrane.

    Abstract translation: 与TNF-NGF家族的其他受体相互作用的配体，抑制肿瘤坏死因子的杀细胞活性而不是与TNF-R结合的肿瘤坏死因子受体（TNF-Rs）的抗体与生产它们的方法一起提供。 抗体优选结合p75 TNF受体的第四半胱氨酸富集结构域或所述第四富含半胱氨酸的结构域与细胞膜之间的区域。

    Immunogenic compositions for induction of anti-tumor immunity
    190.
    发明申请
    Immunogenic compositions for induction of anti-tumor immunity 失效
    用于诱导抗肿瘤免疫的免疫原性组合物

    公开(公告)号：US20020197270A1

    公开(公告)日：2002-12-26

    申请号：US10032482

    申请日：2002-01-02

    Applicant: Yeda Research and Development Co. Ltd.

    Inventor： Irun R. Cohen ,  Varda Rotter ,  Roland Wolkowicz ,  Pedro Ruiz ,  Neta Erez-Alon ,  Johannes Herkel

    IPC: A61K048/00 ,  A61K039/00

    CPC classification number: C07K16/30 ,  A61K39/00 ,  A61K2039/505 ,  A61K2039/51 ,  C07K16/18 ,  C07K2317/565 ,  C07K2317/73

    Abstract: The invention relates to the use of an immunogen selected from the group consisting of (i) an anti-p53 mAb; (ii) a fragment of an anti-p53 mAb; (iii) a peptide based on a CDR of the heavy or light chain of an anti-p53 mAb, which peptide is capable of eliciting antibodies to p53; and (iv) a DNA molecule coding for the variable (V) region of an anti-p53 mAb in a suitable gene delivery vehicle, for the preparation of a pharmaceutical composition useful for induction of anti-tumor immunity in mammals, for activating an enhanced immune response to a p53 molecule in mammals, and/or for induction of immune responses to mutated and wild-type forms of a p53 in mammals. The use of anti-p53 mAbs and novel peptides based on the CDR2 and CDR3 of the heavy chains and CDR3 of the light chains of different anti-p53 mAbs are disclosed.

    Abstract translation: 本发明涉及选自以下的免疫原的用途：（i）抗p53 mAb; （ii）抗p53 mAb的片段; （iii）基于抗p53 mAb的重链或轻链的CDR的肽，该肽能够引发针对p53的抗体; 和（iv）编码合适的基因递送载体中抗p53mAb的可变（V）区的DNA分子，用于制备用于诱导哺乳动物抗肿瘤免疫的药物组合物，用于激活增强的 对哺乳动物中p53分子的免疫应答，和/或用于诱导哺乳动物中突变​​和野生型形式的p53的免疫应答。 公开了使用抗p53 mAb和基于不同抗p53 mAb的轻链的CDR2和CDR3的CDR3和新型肽。

Patent Agency Ranking